An evaluation of the tolerability and feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary Glioblastoma (GALA-5 Trial)

Trial Profile

An evaluation of the tolerability and feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary Glioblastoma (GALA-5 Trial)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Aminolevulinic acid (Primary) ; Carmustine polifeprosan 20 wafer (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Acronyms GALA-5
  • Most Recent Events

    • 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials record.
    • 07 Dec 2015 Planned primary completion date changed from 1 May 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
    • 22 Jun 2013 Accrual to date is 105% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top